IPAs & physician groups
Bring personalized medication guidance to your patients and network. Practices launch in two phases, with enrollment, kits, patient targeting and branded materials provided.
Medication safety
Catch drug-gene interactions before they affect treatment.
Personalized care
Recommendations tailored to each patient's genetic profile.
Stronger partnerships
Share actionable insights with co-providers and pharmacists.
Decision support
Clinical guidance your prescribers can act on.
Two phases to launch
- Phase 1 · Initiation
Enroll and get kits
Complete the physician enrollment form to register your practice. Collection kits ship to you.
- Phase 2 · Start-up
Identify patients and promote
Build a patient identification strategy and deploy the PGx index card, branded for your practice.
- Launch
Test and track outcomes
Begin testing and document outcomes across your network.
Start with high-priority medications
Focus first on drugs with the strongest FDA labeling for gene-drug risk, such as clopidogrel and codeine. They make a practical starting point.
Clopidogrel (Plavix®)
A prodrug that needs CYP2C19 to become active. Poor metabolizers may get inadequate antiplatelet protection and a higher risk of cardiovascular events.
Other drugs with established PGx associations:
Ready-to-use launch materials
- Physician enrollment form. Captures physician, practice and contact details and registers you in the program.
- Sample collection kits. Shipped to your office after enrollment.
- Patient identification strategy. Starts with black-box and high-risk medications.
- PGx index card. Branded for your practice, it introduces PGx to patients and prompts them to ask about testing.
Do your medications work for your genes?
One quick cheek swab can show how your body processes common medications. Ask your doctor about PGx testing today.